Calypso Biotech is an immunotherapy biotech company, spin-off from Merck Serono, that discovers and develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs.
Calypso Biotech’s lead program, CALY-002, is a clinical stage best-in-class therapeutic antibody that binds to and neutralizes interleukin-15 (IL-15). IL-15 plays multiple roles in the immune system by controlling the homeostasis and activation of T, B, NK but also has recently emerged as a key driver of disease-perpetuating tissue resident memory T cells. Thus, CALY-002 has the potential to be a game-changing treatment in multiple indications.
The current clinical program for CALY-002 focuses on two gastrointestinal indications characterized by large unmet needs and driven by dysregulated expression of IL-15:
Our vision is to develop CALY-002 as a “pipeline-in-a drug” value proposition beyond gastro-enterology, with current preclinical studies conducted in immuno-dermatology.
Calypso Biotech is headquartered in Amsterdam (The Netherlands) and has offices and laboratories in Geneva (Switzerland). Calypso Biotech is also a resident company of Johnson & Johnson Innovation JLABS at Beerse in Belgium (JLABS@BE).
Chief Executive Officer, Co-founder
Dr Vicari co-founded Calypso Biotech in 2013. Prior to Calypso Biotech, he accumulated more than 15 years international experience in translational immunology and drug discovery at Merck Serono, Pfizer Vaccines, Coley Pharmaceutical Group and Schering-Plough.
Dr Vicari received a Doctor in Veterinary Medicine degree from the Ecole Nationale Vétérinaire de Lyon and a PhD in Immunology from the Université Claude Bernard, Lyon. He completed post-doctoral training at the DNAX Research Institute (Palo Alto, California).
Chief Medical Officer
Jos Houbiers, MD, PhD brings to Calypso Biotech over 20 years of experience in pharmaceutical development and over 30 years of academic and pharma clinical trial experience. He has designed and implemented medical development strategies, creative trial designs and comprehensive drug safety surveillance and medical safety monitoring strategies across multiple therapeutic areas including rheumatology, immunology, transplantation, hematology, oncology and functional urology. He was most recently Chief Medical Officer at Summit Therapeutics. Dr. Houbiers has received his MD from Leiden University Medical Center and PhD (immunology/oncology) and MSc in medicine from Leiden University and gained medical specialist experience in internal medicine.
Chief Business Officer
Nicolas Guyon-Gellin (M.D., MSc) brings Calypso Biotech more than 10 years of expertise in global Healthcare financial markets as an equity research analyst for Morgan Stanley London, Exane BNP and Amundi Paris and 5 years of Biotech Business Development and Strategy expertise for ENYO Pharma.
Dr Guyon-Gellin has received his M.D. from Université Paris Descartes (Paris V) as a General Practitioner and Master degree (MSc) from ESCP Europe.
Associate Professor of Medicine and Epidemiology, Department of Medicine, Division of Gastroenterology and Hepatology, UNC Chapel Hill, USA.
Consultant Gastroenterologist, AMC Amsterdam.
President-elect European EoE Society EUREOS, The Netherlands.
Professor of Gastroenterology and Internal Medicine, University of Basel, Chair of Swiss EoE Research Group and of the Swiss Eosinophilic Esophagitis Research Network, Switzerland.
AConsultant gastroenterologist at University Hospitals Leuven and associate professor of medicine at KU Leuven, Belgium. He is the medical lead of the Leuven Intestinal Failure and Transplantation center (LIFT) and his research focus on pathophysiology of intestinal failure and functional gastrointestinal disorders
Chief of the Division of Pediatric Gastroenterology and Nutrition, director of the Mucosal Immunology and Biology Research Center at Mass General for Children and professor of nutrition at Harvard T.H. Chan School of Public Health. His research focuses on bacterial pathogenesis, gut microbiome composition and function in health and disease, regulation of gut permeability, biology and immunology and SARS-CoV2. He is widely sought after as an expert in celiac disease, intestinal permeability and autoimmune disorders.
Professor emeritus at the Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland and presently also PI at the Tampere university Celiac Disease Research Center CeliRes, with focus area Novel treatments.
Thierry Passeron MD, PhD, is Professor and chair of Dermatology in the University hospital of Nice. He also heads the laboratory INSERM U1065 team 12, C3M, dedicated to the study of molecular mechanisms involved in pigmentation and melanoma. He heads the University laser center in Nice. He is president of the Department of Clinical Research and Innovation of Nice University hospital and vice-president of Côte d’Azur University. He has 12 international patents and more than 320 publications in scientific journals (h-index 54). He is the co-founder of YUKIN therapeutics. His fields of research include pigmentary disorders (including vitiligo and melasma), melanoma, hidradenitis suppurativa, alopecia areata and lasers.
Dr Julien Seneschal is Professor of Dermatology at the Department of Dermatology, National Reference Center for Rare Skin Diseases, University of Bordeaux. He is the head of the Inflammatory and Auto-Immune Skin Disorders Unit and is responsible for the Vitiligo and Pigmentary disorders clinic and is leader of the immune-dermatology research team at CNRS UMR 5164 ImmunoConCept unit, University of Bordeaux.
Professor of dermatology and allergy and director of the Institute of Allergology at the Charité Universitätsmedizin Berlin; Director of the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany; chairman of the board of the European Centre for Allergy Research Foundation and President of the international GA²LEN network
Professor of Pulmonary Medicine at ErasmusMC and at UGent, Belgium, and since 2012 the director of the VIB Inflammation Research Center, hosting 250 scientists . He is an ERC grant awardee and serves on the editorial board of Mucosal Immunology, Trends in Immunology and Journal of Experimental Medicine. He has (co)authored 310 papers in the field of asthma and allergy.
Clinical Trial Leader
Isabelle Tran joined Calypso Biotech in 2020 as Clinical Trial Leader. Prior to Calypso Biotech, Isabelle accumulated more than 20 years international experience in the pharmaceutical industry at Pfizer, PregLem , Prexton Therapeutics and Lundbeck. She has developed an expertise in Clinical Operations specialising in Early Clinical Development across multiples therapeutics areas including Women’s Health and Neuroscience.
Isabelle gained a double engineering and research MSc degree from the French Grandes Ecoles d’Ingénieurs (ESPCI) and the Paris V University. She is also fully trained in Project Management.
Head of CMC
Wiktor Banachewicz joined Calypso Biotech in 2023. He has extensive international biopharmaceutical development experience from preclinical to the commercial stage in both large pharma and small biotech including Roche, Sandoz and VectivBio. Wiktor graduated from Warsaw University in Organic Chemistry and Molecular Biology and received his Ph.D. in Molecular Biophysics from the University of Cambridge.
Biologics manufacturing Advisor
Greg Elson is an expert consultant specialized in biologics product and CMC development. Greg has a PhD in molecular immunology with more than 25 years of experience in biopharmaceutical R&D with managerial experience in drug development. Greg’s initial experience was in biologics product discovery and technology platform development. Subsequently, he held discovery leadership roles whilst concomitantly building cross-functional teams within the Biologics CMC departments that he headed. Greg’s current experience in biologics product development leadership was progressively gained through management roles within cutting edge biologics development organizations such as NovImmune and Glenmark.
Strategic planning and Quality Advisor
Duc Tran brings twenty years of experience in drug discovery and drug development in working for big pharma companies (Sanofi-Aventis, Pfizer) and start-ups (Preglem, Arisgen, EspeRare, Prexton Therapeutics) in various disease areas encompassing cardiovascular, anti-infective, urology, epigenetics, CNS, rare disease and reproductive medicine, delivering a large number of projects into clinical development up to registration. Duc provides independent advice to design and implement regulatory strategy, pre-clinical and clinical plans, ensuring rapid proof of concept to full development, maintaining a high standard and compliance with regards to the ethics and regulatory principles.
Duc is graduated from the French Grandes Ecoles d’ingénieurs ESPCI in Physics, Chemistry and Biology. Duc also holds a MSc degree in organic and bioorganic chemistry from Paris VI and is a registered Project Manager.
Susana holds a PhD in Biomedical Sciences and has more than 15 years’ experience in basic and translational research. Over the past 10 years in the Biopharmaceutical Industry Susana has contributed to the non-clinical development of 10 therapeutic antibody candidates in the inflammatory and immuno-oncology fields, from discovery all the way to marketing application.
Before moving into the Biopharmaceutical Industry, Susana worked as a Research Scientist in the US at the Genomics Institute of the Novartis Research Foundation and earned her PhD degree from the University of Oxford (UK). She then relocated to Europe and worked for the World Health Organization and Novimmune SA, both in Geneva, Switzerland.
At Novimmune for 9 years, Susana worked as Head of Non-clinical Safety and Program Manager. As Head of Non-clinical Safety, Susana was responsible for the early characterization and safety assessment of mono and bi-specific antibodies, designing and monitoring in vitro and in vivo IND-enabling studies. She was also involved in writing of non-clinical sections of regulatory documents and preparing CTA/IND submissions. As Program Manager, she was in charge of the cross-functional coordination within Project Teams and gained extensive experience in preclinical Outsourcing, from CRO selection to delivery of regulatory-compliant datasets and reports.
Independent Chairman of the Board
Bernard Coulie, M.D., Ph.D., is currently serving as President and Chief Executive Officer of Pliant Therapeutics. Under his leadership, Pliant raised $124 Million in venture and private equity capital so far. He joined Pliant from ActoGeniX, where he was CEO, Chief Medical Officer and Co-Founder. In these positions, Dr. Coulie played an integral role in advancing the company’s unique technology platform for oral delivery of biologics from early discovery stage through Phase 2 studies. Prior to ActoGeniX, Dr. Coulie held various positions at Johnson & Johnson Pharmaceutical Research and Development Europe where he managed a portfolio of products in GI, metabolic diseases and inflammation/immunology. Dr. Coulie was trained as a gastroenterologist at University of Leuven (Belgium) and at Mayo Clinic (Rochester, MN).
Based in Amsterdam, The Netherlands, and a subsidiary of Merck KGaA, Darmstadt, Germany, M Ventures is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck KGaA, Darmstadt, Germany‘s core business areas. From our headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success.
INKEF Capital is a leading venture capital firm based in Amsterdam with a proven history in backing promising early stage companies in Europe. INKEF takes pride in being a patient, long-term investor with the ability to support companies through several funding rounds all the way up to IPO. From the early stages of being a technology or life science venture, INKEF supports entrepreneurs building their ideas into successful international businesses. Inkef’s investments include Onward Medical, Castor, iOnctura, Cardior and GitLab, Remote among others. For more information please visit: www.inkef.com
Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in digital health, medtech and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and DACH-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market.
Alex LeBeaut was most recently Executive Vice-President of R&D and CSO, Ipsen. Before joining Ipsen, Dr LeBeaut held several global leadership positions in clinical development and medical affairs with biopharmaceutical companies including Bluebird Bio, Axcan Pharmaceuticals, Sanofi, Novartis and Schering Plough Research Institute.
Johnson & Johnson Innovation – JJDC, Inc. is the venture capital subsidiary of Johnson & Johnson that has been investing since 1973 in the medical device, diagnostic, pharmaceutical, and consumer health areas. JJDC’s goal is to create opportunities that meet the strategic needs of its operating affiliates while providing visibility to innovative emerging technology, businesses and business models. JJDC invests in companies across the continuum from early stage seed investments to advanced stages of series venture management.
Fountain Healthcare Partners
Fountain Healthcare Partners is a life science focused venture capital fund with EUR 300 million (USD 354 million) under management. Within the life science sector, specific areas of interest to Fountain include specialty pharma, medical devices, biotechnology and diagnostics. The firm deploys the majority of its capital in Europe, with the balance in the United States. Fountain’s main office is in Dublin, Ireland, with a second office in New York.